News

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
Danish leader will face a challenging landscape among competitors ...
Novo Nordisk A/S (NVO) Could Lose To Eli Lilly, Warns Jim Cramer
We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer ...
Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem.
The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.
Why Novo Nordisk Stock Bumped Higher on Friday
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Why Novo Nordisk Stock Crumbled Again Today
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...